Seattle Flow Your front door to Seattle's startup scene.
Sign in
Stream Events Podcasts Videos Communities Founder Stack
BrainChild Bio, Inc.

BrainChild Bio Raises $116M Series A to Fund Pivotal Phase 2 Trial of BCB-276 CAR T Therapy for DIPG

BrainChild Bio, spun out of Seattle Children’s, is advancing B7-H3–targeting CAR T-cell therapies for incurable pediatric brain tumors and has raised $116 million to fund a pivotal Phase 2 trial of BCB-276 for DIPG.

BBrainChild Bio, Inc.
  • Link
  • Report this item
  • Seattle Flow
  • LinkedIn
  • X
  • Threads
  • Bluesky
Replying to

No comments yet.

Seattle Flow — Your front door to Seattle's startup scene.

Run by Marcelo Calbucci MC
About Manifesto Startup Day 2026 Send us a link Terms of Service Privacy For AI assistants Contact
© 2026 Seattle Flow, a service of The Fold. All rights reserved.

We love feedback!

Sign in or sign up to leave feedback

Who liked this

Edit history

Seattle Flow

Your front door to Seattle's startup scene.

Seattle's startup scene is scattered across a hundred feeds, newsletters, and calendars. Seattle Flow brings it together: the news, events, podcasts, and people, plus what the community is saying about them. Every link sends you to the source.

Writing about a Seattle founder, fund, or startup? We'll help it get seen. Found a great story we missed? Send it in.

We're in beta and building this with the community. Tell us what you want to see here.

Seattle's startup scene, every day. The news, events, podcasts, and people, plus what everyone's saying about them. We're in beta: send us a story or tell us what you want to see.